Hogan Lovells advised EyePoint Pharmaceuticals on the offering. Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a clinical-stage biopharmaceutical company, announced its US$161 million follow-on public offering of 14,636,363...
You must be a Standard 1 Year member to access this content.
Lazard is acting as the exclusive financial advisor to Collegium. Hogan Lovells is serving as M&A legal counsel to Collegium. Goodwin Procter LLP is serving as...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Perspective Therapeutics on the deal. Perspective Therapeutics (NYSE AMERICAN: CATX) has completed an underwritten offering of 51,515,880 shares of its common stock at...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Perspective Therapeutics on a series of strategic transactions. Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) has completed a series of strategic transactions with Lantheus Holdings (NASDAQ:...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised EyePoint Pharmaceuticals on its offering. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) closed its US$230 million follow-on public offering of 13,529,411 shares of common stock...
You must be a Standard 1 Year member to access this content.
